Concomitant use of antipsychotics and drugs that may prolong the QT interval

被引:25
|
作者
Roe, CM
Odell, KW
Henderson, RR
机构
[1] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Alzheimer Dis Res Ctr, St Louis, MO 63110 USA
[3] Express Scripts Inc, Bloomington, MN USA
[4] Express Scripts Inc, St Louis, MO USA
关键词
D O I
10.1097/00004714-200304000-00013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Concomitant use of drugs that prolong the QT interval is a risk factor for torsades de pointes, a ventricular arrhythmia associated with sudden death. This study compared the concomitant use of drugs that may prolong the QT interval ("other QT drugs") among two groups of patients: one that took antipsychotics that may prolong the QT interval (the QT antipsychotic group, n = 1,750) and one that used antipsychotics that do not result in QT prolongation (the non-QT antipsychotic group, n = 1, 139). Data were pharmacy claim and eligibility information from January 1, 2000, through December 31, 2000, from a research database of a large pharmacy benefit manager. Concomitant use of antipsychotics and other QT drugs was examined for each participant over a 3- to 12-month follow-up period. Results showed that 5 1 % of QT antipsychotic group members used other QT drugs concomitantly for at least I day in the follow-up period. Logistic regression indicated that there was no significant difference between the QT antipsychotic and non-QT antipsychotic groups with concomitant use of other QT drugs when potential confounders were controlled (p = 0.6013). Although female sex is a risk factor for drug-induced torsades de pointes, women were more likely to concomitantly use other QT drugs than men in both the QT (56.2% vs. 43.2%; p < 0.001) and non-QT (53.1% vs. 43.0%;p < 0.001) antipsychotic groups. Findings suggest that the use of other QT drugs is not being minimized among patients taking QT antipsychotics.
引用
收藏
页码:197 / 200
页数:4
相关论文
共 50 条
  • [21] Safety of non-antiarrhythmic drugs that prolong the QT interval or induce Torsade de Pointes an overview
    De Ponti, F
    Poluzzi, E
    Cavalli, A
    Recanatini, M
    Montanaro, N
    DRUG SAFETY, 2002, 25 (04) : 263 - 286
  • [22] Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview
    De Ponti F.
    Poluzzi E.
    Cavalli A.
    Recanatini M.
    Montanaro N.
    Drug Safety, 2002, 25 (4) : 263 - 286
  • [23] Concomitant use of antipsychotics with risperidone
    Chouinard, G
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (04) : 443 - 443
  • [24] QT INTERVAL PROLONGATION IN AN INPATIENT POPULATION RECEIVING ANTIPSYCHOTICS
    Rincon, Erika
    Alberto Miranda, Carlos
    Carlos Rivas, Juan
    Galindo, Juliana
    Fernando Zambrano, Luis
    Maria Rivas, Ana
    Milena Ramirez, Sandra
    Hernandez, Mauricio
    Perafan, Pablo
    Gomez Mesa, Juan Esteban
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 469 - 469
  • [26] Antipsychotics treatment continuation in patients with QT interval prolongation
    Pereira Vaz De Macedo, P. A.
    Borges, J.
    Leite, R.
    Dias dos Santos, G.
    Almeida, M.
    Mesquita Figueiredo, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S478 - S479
  • [27] Pregbalin induced recurrent syncopal attacks with prolong QT interval
    Adar, Adem
    Cakan, Fahri
    Onalan, Orhan
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2018, 23 (04)
  • [28] Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium
    Vandael, Eline
    Marynissen, Thomas
    Reyntens, Johan
    Spriet, Isabel
    Vandenberghe, Joris
    Willems, Rik
    Foulon, Veerle
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (04) : 757 - 765
  • [29] Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium
    Eline Vandael
    Thomas Marynissen
    Johan Reyntens
    Isabel Spriet
    Joris Vandenberghe
    Rik Willems
    Veerle Foulon
    International Journal of Clinical Pharmacy, 2014, 36 : 757 - 765
  • [30] Antipsychotic Drugs and QT Interval Prolongation
    Wojciech Zareba
    David A. Lin
    Psychiatric Quarterly, 2003, 74 : 291 - 306